Cargando…

Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension

Ivabradine, the selective inhibitor of the If current in the sinoatrial node, exerts cardiovascular protection by its bradycardic effect and potentially pleiotropic actions. However, there is a shortage of data regarding ivabradine’s interaction with the renin-angiotensin-aldosterone system (RAAS)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Simko, Fedor, Baka, Tomas, Poglitsch, Marko, Repova, Kristina, Aziriova, Silvia, Krajcirovicova, Kristina, Zorad, Stefan, Adamcova, Michaela, Paulis, Ludovit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212851/ https://www.ncbi.nlm.nih.gov/pubmed/30282928 http://dx.doi.org/10.3390/ijms19103017

Ejemplares similares

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension
por: Simko, Fedor, et al.
Publicado: (2018)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
por: Simko, Fedor, et al.
Publicado: (2022)

Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension
por: Stanko, Peter, et al.
Publicado: (2020)

Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol‐induced myocardial injury
por: Simko, Fedor, et al.
Publicado: (2020)

Hypertension and Cardiovascular Remodelling in Rats Exposed to Continuous Light: Protection by ACE-Inhibition and Melatonin
por: Simko, Fedor, et al.
Publicado: (2014)

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril
por: Simko, Fedor, et al.
Publicado: (2017)

Renin–Angiotensin–Aldosterone System: Friend or Foe—The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions
por: Simko, Fedor, et al.
Publicado: (2021)

Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril
por: Repova, Kristina, et al.
Publicado: (2022)

Cardiovascular therapeutics: A new potential for anxiety treatment?
por: Repova, Kristina, et al.
Publicado: (2022)

Melatonin as a Potential Approach to Anxiety Treatment
por: Repova, Kristina, et al.
Publicado: (2022)

Therapeutic perspectives in hypertension: novel means for renin–angiotensin–aldosterone system modulation and emerging device-based approaches
por: Unger, Thomas, et al.
Publicado: (2011)

Activation of the Renin–Angiotensin–Aldosterone System Is Attenuated in Hypertensive Compared with Normotensive Pregnancy
por: Shoemaker, Robin, et al.
Publicado: (2023)

The Impact of microRNAs in Renin–Angiotensin-System-Induced Cardiac Remodelling
por: Adamcova, Michaela, et al.
Publicado: (2021)

New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?
por: Paulis, Ludovit, et al.
Publicado: (2015)

Melatonin as a rational alternative in the conservative treatment of resistant hypertension
por: Simko, Fedor, et al.
Publicado: (2019)

Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension
por: Moon, Ju-Young
Publicado: (2013)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Ivabradine and Blood Pressure Reduction: Underlying Pleiotropic Mechanisms and Clinical Implications
por: Simko, Fedor, et al.
Publicado: (2021)

Angiotensin A/Alamandine/MrgD Axis: Another Clue to Understanding Cardiovascular Pathophysiology
por: Hrenak, Jaroslav, et al.
Publicado: (2016)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
por: Kang, Si-Hyuck, et al.
Publicado: (2021)

Renin-Angiotensin Aldosterone System and Hypertension: Current Approaches and Future Directions
por: Flack, John M., et al.
Publicado: (2007)

Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension
por: Andersen, Karl
Publicado: (2009)

The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension
por: Wang, Hui-Bo, et al.
Publicado: (2015)

Circulating renin‐angiotensin‐aldosterone system activity in cats with systemic hypertension or cardiomyopathy
por: Ward, Jessica L., et al.
Publicado: (2022)

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022)

Are "functionally related polymorphisms" of renin-angiotensin-aldosterone system gene polymorphisms associated with hypertension?
por: Hahntow, Ines N, et al.
Publicado: (2010)

Targeting the Renin–Angiotensin–Aldosterone System to Prevent Hypertension and Kidney Disease of Developmental Origins
por: Hsu, Chien-Ning, et al.
Publicado: (2021)

Regulation of human salt-sensitivite hypertension by myeloid cell renin-angiotensin-aldosterone system
por: Ertuglu, Lale A., et al.
Publicado: (2023)

SAT-066 Effect Of Interleukin-1-receptor Antagonist On Hemodynamics And Renin-angiotensin-aldosterone System In Obese Individuals
por: Urwyler, Sandrine, et al.
Publicado: (2019)

Renin, Aldosterone, and Cortisol in Pregnancy-Induced Hypertension
por: Lewandowski, Krzysztof C, et al.
Publicado: (2023)

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure
por: Arendse, Lauren B., et al.
Publicado: (2019)

Contribution of Four Polymorphisms in Renin-Angiotensin-Aldosterone-Related Genes to Hypertension in a Thai Population
por: Charoen, Pimphen, et al.
Publicado: (2019)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension
por: Xu, Wei, et al.
Publicado: (2022)

Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors
por: Golpe, Rafael, et al.
Publicado: (2020)

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
por: Drobni, Zsofia D., et al.
Publicado: (2022)

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers
por: Vazquez-Agra, Nestor, et al.
Publicado: (2023)

Sex differences in the renin-angiotensin-aldosterone system and its roles in hypertension, cardiovascular, and kidney diseases
por: Nwia, Sarah M., et al.
Publicado: (2023)

Evaluation of Renin–Angiotensin–Aldosterone System Components and Enzymes in Systemically Hypertensive Cats Receiving Amlodipine
por: Adin, Darcy, et al.
Publicado: (2023)

Renin, aldosterone, the aldosterone-to-renin ratio, and incident hypertension among normotensive subjects from the general population
por: Arnold, Natalie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_25ks7pvdu7b5ah59gcunsg9hqm